Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.64 |
| ▸ | AGXT | P21549 | 2/20 | 0.64 |
| ▸ | MAOB | P27338 | 11/20 | 0.60 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.50 |
| ▸ | MAOA | P21397 | 3/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.46 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1767187 | 0.82 | IDO1 (0.69) | IDO1AGXTMAOBTAAR1MAOA | |
| SCHEMBL3159482 | 0.79 | IDO1 (0.60) | IDO1AGXTMAOBTAAR1MAOA | |
| SCHEMBL12256032 | 0.78 | MAOB (0.66) | IDO1AGXTMAOBTAAR1MAOA | |
| SCHEMBL1520772 | 0.78 | IDO1 (1.00) | IDO1AGXTMAOBTAAR1 | |
| SCHEMBL9347048 | 0.78 | IDO1 (0.64) | IDO1AGXTMAOBTAAR1MAOA | |
| SCHEMBL29830809 | 0.78 | IDO1 (0.64) | IDO1AGXTMAOBTAAR1MAOA | |
| SCHEMBL514760 | 0.78 | IDO1 (0.64) | IDO1AGXTMAOBTAAR1MAOA | |
| SCHEMBL31568444 | 0.77 | TSHR (0.62) | IDO1AGXTMAOBTAAR1MAOA | |
| SCHEMBL22469745 | 0.77 | TSHR (0.62) | IDO1AGXTMAOBTAAR1MAOA | |
| SCHEMBL6291712 | 0.77 | IDO1 (0.62) | IDO1AGXTMAOBTAAR1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6274715-B1 | SEMISYNTHETIC MACROLIDES, USEFUL IN BACTERIAL INFECTIONS TREATMENT AND PREVENTION, HAS LESS POTENTIAL FOR DEVELOPING RESISTANCE, IMPROVED OR MODIFIED PROFILES OF DESIRED GRAM-NEGATIVE ACTIVITY | ABBOTT LABORATORIES | 2001-08-14 | — | — | US | claimed |
| CN-1244202-A | Tricyclic erythromycin derivatives | ABBOTT LAB (US) | 2000-02-09 | — | — | CN | claimed |
| EP-0961776-A1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | Abbott Laboratories (US) | 1999-12-08 | — | — | EP | claimed |
| WO-1998030574-A1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 1998-07-16 | — | — | WO | claimed |
| WO-2023210623-A1 | HALOALKYL SULFONE ANILIDE COMPOUND AND HERBICIDE CONTAINING SAME | 株式会社エス・ディー・エス バイオテック | 2023-11-02 | — | — | WO | disclosed |
| WO-2014184070-A1 | MIXTURES OF HALOALKYLSULFONANILIDE DERIVATIVES AND HERBICIDES | SYNGENTA LIMITED (GB) | 2014-11-20 | — | — | WO | disclosed |
| WO-2014184071-A1 | MIXTURES OF HALOALKYLSULFONANILIDE DERIVATIVES AND HERBICIDES | SYNGENTA LIMITED (GB) | 2014-11-20 | — | — | WO | disclosed |
| EP-2420493-A1 | HALOALKYLSULFONANILIDE DERIVATIVE | Nissan Chemical Industries, Ltd. (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-20120029187-A1 | HALOALKYLSULFONANILIDE DERIVATIVE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
| EP-2336104-A1 | ORTHO-SUBSTITUTED HALOALKYLSULFONANILIDE DERIVATIVE AND HERBICIDE | Nissan Chemical Industries, Ltd. (JP) | 2011-06-22 | — | — | EP | disclosed |
| US-7342031-B2 | Thiadiazole compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-03-11 | — | — | US | disclosed |
| US-20070293510-A1 | Thiadiazole compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED ( A JAPANESE CORPORATION) (JP) | 2007-12-20 | — | — | US | disclosed |
| CN-1244202-A | Tricyclic erythromycin derivatives | ABBOTT LAB (US) | 2000-02-09 | — | — | CN | disclosed |
| EP-0961776-A1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | Abbott Laboratories (US) | 1999-12-08 | — | — | EP | disclosed |
| US-5972946-A | NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1999-10-26 | — | — | US | disclosed |
| WO-1998030574-A1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 1998-07-16 | — | — | WO | disclosed |
| EP-0826673-A1 | ACETAMIDE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL COMPOSITION CONTAINING THE SAME | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1998-03-04 | — | — | EP | disclosed |
| EP-0003261-B1 | OXADITHIADIAZAPENTALENES, THEIR PREPARATION, FUNGICIDAL COMPOSITIONS CONTAINING THEM AND THE CONTROL OF FUNGI USING THEM | CHEVRON RESEARCH COMPANY (US) | 1981-12-30 | — | — | EP | disclosed |
| US-4179441-A | REACTING SULFUR HALIDE WITH N-CYANOMETHYLCARBOXAMIDE; CYCLIZATION | CHEVRON RESEARCH COMPANY (US) | 1979-12-18 | — | — | US | disclosed |
| EP-0003261-A1 | Oxadithiadiazapentalenes, their preparation, fungicidal compositions containing them and the control of fungi using them | CHEVRON RESEARCH COMPANY (US) | 1979-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029187-A1 | HALOALKYLSULFONANILIDE DERIVATIVE | CBR3, CBR1, HDHD5 | IDO1 2656/4885AGXT 651/4885MAOB 3755/4885 |
| US-20070293510-A1 | Thiadiazole compounds and use thereof | C5, C3AR1, TH | IDO1 912/4885AGXT 1290/4885MAOB 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.